People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.0M | 2012 |
| Femasys Inc | — | Biotechnology | Series B | $74.7M | $32.0M | 2023 |
| Cellectar Biosciences, Inc. | — | Pharmaceuticals | Series B | $72.6M | $236.3M | 2020 |
DOV ELEFANT at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside DOV ELEFANT on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Silverman | 1 | 8 |
| David Sidransky | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| Charles Larsen | 1 | 7 |
| Samir Patel | 1 | 7 |
| JAMES HILL | 1 | 6 |
| John Adams | 1 | 6 |
| Parker H. Petit | 1 | 5 |
| MARK COHEN | 1 | 5 |
| DOUGLAS J. SWIRSKY | 1 | 5 |
| Donald Williams | 1 | 4 |
| Michael J. Doyle | 1 | 4 |
| Yuval Cohen | 1 | 4 |
| Wendy DiCicco | 1 | 4 |
| Gary Thompson | 1 | 4 |
| Thomas Rockwell Mackie | 1 | 4 |
| Fred Aslan | 1 | 3 |
| Johnson Lau | 1 | 3 |
| Simon Pedder | 1 | 3 |
| James S. Manuso | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.